TALS RSI Chart
Last 7 days
5.9%
Last 30 days
1.1%
Last 90 days
-6.8%
Trailing 12 Months
16.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jul 03, 2023 | fenton mary kay | sold (taxes) | -39,873 | 3.08 | -12,946 | chief financial officer |
Jul 03, 2023 | requadt scott | sold (taxes) | -36,300 | 3.08 | -11,786 | - |
Jun 14, 2023 | ildstad suzanne | sold | -32,243 | 2.4914 | -12,942 | - |
Jun 13, 2023 | ildstad suzanne | sold | -36,338 | 2.5576 | -14,208 | - |
Jun 12, 2023 | ildstad suzanne | sold | -43,725 | 2.5919 | -16,870 | - |
Jun 09, 2023 | ildstad suzanne | sold | -62,637 | 2.4642 | -25,419 | - |
Jun 08, 2023 | ildstad suzanne | sold | -100,772 | 2.4795 | -40,642 | - |
Jun 07, 2023 | ildstad suzanne | sold | -179,095 | 2.3879 | -75,001 | - |
Jun 06, 2023 | ildstad suzanne | sold | -64,595 | 2.5283 | -25,549 | - |
Jun 05, 2023 | ildstad suzanne | sold | -19,754 | 2.5194 | -7,841 | - |
Which funds bought or sold TALS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Oct 30, 2023 | FREEDOM WEALTH ALLIANCE, LLC | new | - | 45,367 | 45,367 | 0.07% |
Jul 22, 2022 | Altium Wealth Management LLC | unchanged | - | -318,000 | 268,000 | 0.02% |
May 16, 2022 | Amalgamated Financial Corp. | new | - | 31,000 | 31,000 | -% |
Unveiling Talaris Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Talaris Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Talaris Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 |
Revenue | - | 538 | - | - | - | - |
Operating Expenses | -42.6% | 9,470 | 16,502 | 24,078 | -36,951 | 19,823 |
S&GA Expenses | 51.2% | 9,114 | 6,026 | 6,182 | -12,113 | 4,842 |
R&D Expenses | -97.0% | 267 | 8,800 | 13,415 | -24,838 | 14,981 |
Net Income | 52.4% | -7,015 | -14,738 | -22,497 | 35,665 | -19,011 |
Free Cashflow | 49.7% | -7,502 | -14,919 | -17,222 | 43,235 | -13,768 |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | 70.8% | 359 | 210 | 151 | 159 | 173 | 190 | 207 | 221 | 237 | 251 | 261 | 273 | 145 | 153 |
Current Assets | 43.7% | 300 | 209 | 151 | 156 | 169 | 8.00 | 198 | 212 | 228 | 247 | 258 | 270 | 143 | 151 |
Cash Equivalents | -30.0% | 99.00 | 141 | 67.00 | 18.00 | 24.00 | 8.00 | 18.00 | 26.00 | 23.00 | 0.00 | 27.00 | 36.00 | 10.00 | 18.00 |
Net PPE | -11.8% | 0.00 | 0.00 | - | 0.00 | 3.00 | 0.00 | 5.00 | 6.00 | 5.00 | 5.00 | 3.00 | 2.00 | 2.00 | 2.00 |
Liabilities | -4.2% | 5.00 | 5.00 | 8.00 | 11.00 | 11.00 | 2.00 | 12.00 | 10.00 | 11.00 | 9.00 | 6.00 | 5.00 | 5.00 | 5.00 |
Current Liabilities | -3.5% | 5.00 | 5.00 | 8.00 | 10.00 | 10.00 | 1.00 | 9.00 | 7.00 | 8.00 | 8.00 | 5.00 | 5.00 | 4.00 | 3.00 |
Shareholder's Equity | 72.7% | 354 | 205 | 143 | 148 | 162 | 180 | 195 | 211 | 226 | 243 | 256 | 267 | - | - |
Retained Earnings | -21.5% | -75.36 | -62.05 | -208 | -201 | -187 | -19.93 | -146 | -127 | -109 | -90.85 | -76.61 | -63.70 | -52.30 | -43.01 |
Additional Paid-In Capital | 60.9% | 430 | 267 | 352 | 351 | 349 | 0.00 | 342 | 339 | 336 | 334 | 332 | 331 | 6.00 | 5.00 |
Shares Outstanding | 26.1% | 26.00 | 20.00 | 4.00 | 43.00 | 42.00 | - | 4.00 | 41.00 | 41.00 | 40.00 | 25.00 | 17.00 | - | - |
Float | - | - | - | - | 90.00 | - | - | - | 139 | - | - | - | 280 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -235.4% | -14,923 | 11,021 | -7,502 | -14,698 | -16,902 | 40,529 | -13,427 | -17,280 | -16,280 | -9,842 | -10,129 | -10,982 | -9,047 | -5,650 | -4,826 | -3,493 | -5,243 |
Share Based Compensation | 544.9% | 1,388 | -312 | 1,248 | 1,174 | 3,659 | -7,889 | 3,041 | 2,846 | 2,197 | 994 | 1,053 | 896 | 835 | 593 | 186 | 120 | 123 |
Cashflow From Investing | -113.6% | -188,869 | -88,418 | 55,929 | 8,919 | 27,410 | -51,727 | 6,304 | 19,928 | 20,427 | 721 | 1,694 | -100,132 | 1,330 | -104,363 | -13,048 | 3,566 | -19,455 |
Cashflow From Financing | 3.1% | 161,352 | 156,463 | 74.00 | 137 | 46.00 | 19,668 | 73.00 | 79.00 | 30.00 | 412 | -551 | 137,522 | 17.00 | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 11,376 | $ 6,137 |
General and administrative | 6,141 | 1,365 |
Total operating expenses | 17,517 | 7,502 |
Loss from operations | (17,517) | (7,502) |
Other income, net | 4,206 | 0 |
Net loss | $ (13,311) | $ (7,502) |
Net loss per share, basic (usd per share) | $ (0.55) | $ (8.28) |
Net loss per share, diluted (usd per share) | $ (0.55) | $ (8.28) |
Weighted-average, common shares outstanding, basic (in shares) | 24,082 | 906 |
Weighted-average, common shares outstanding, diluted (in shares) | 24,082 | 906 |
Other comprehensive loss: | ||
Unrealized loss on investments | $ (320) | $ 0 |
Comprehensive loss | $ (13,631) | $ (7,502) |
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 98,286 | $ 140,726 |
Short-term investments | 194,773 | 62,225 |
Prepaid expenses and other current assets | 7,040 | 5,923 |
Total current assets | 300,099 | 208,874 |
Property and equipment, net | 75 | 85 |
Total long-term investments | 57,237 | 0 |
Restricted cash | 227 | 227 |
Operating lease right-of-use asset | 327 | 362 |
Other non-current assets | 1,204 | 747 |
Total assets | 359,169 | 210,295 |
Current liabilities | ||
Accounts payable | 1,936 | 1,071 |
Accrued expenses and other current liabilities | 2,668 | 3,710 |
Operating lease liability, current portion | 223 | 221 |
Total current liabilities | 4,827 | 5,002 |
Operating lease liability, net of current portion | 153 | 194 |
Other liabilities | 50 | 57 |
Total liabilities | 5,030 | 5,253 |
Commitments and Contingencies (Note 11) | ||
Stockholders’ equity | ||
Undesignated preferred stock, $0.0001 par value – 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, no shares issued or outstanding as of March 31, 2024 or December 31, 2023 | 0 | 0 |
Common stock, $0.0001 par value – 140,000,000 voting shares authorized as of March 31, 2024 and December 31, 2023, 25,646,509 and $20,337,571 voting shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; 10,000,000 non-voting shares authorized as of March 31, 2024 and December 31, 2023, no non-voting shares issued or outstanding as of March 31, 2024 or December 31, 2023 | 3 | 2 |
Additional paid-in capital | 429,751 | 267,024 |
Accumulated other comprehensive (loss) income | (253) | 67 |
Accumulated deficit | (75,362) | (62,051) |
Total stockholders’ equity | 354,139 | 205,042 |
Total liabilities and stockholders’ equity | $ 359,169 | $ 210,295 |